Abstract
During recent years, the development of molecular biology has led to the integration of novel, targeted therapies into the treatment of sarcomas. Due to the ever-increasing number of new molecules, the combination of radiographic imaging and specific molecular techniques is a valuable tool in the decision-making process as to whether their development should be continued. Imaging is used for diagnostic purposes, assessment of response, and during follow-up. Special emphasis is given to the new type of so-called “response” not absolutely necessitating tumor shrinkage, driving to development of new response criteria. Functional imaging plays an essential role in these criteria especially in cases where rigorous evaluation is needed for changing therapeutic strategy. Finally, follow-up protocols are described.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Panicek DM, Gatsonis C, Rosenthal DI et al (1997) CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology 202:237–246
Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2012). The ESMO/European Sarcoma Network Working Group. Annals of Oncology 23 (Supplement 7): vii92–vii99
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2012). The ESMO/European Sarcoma Network Working Group. Annals of Oncology 23 (Supplement 7): vii100–vii109
Crim JR, Seeger LL, Yao L et al (1992) Diagnosis of soft tissue masses with MR imaging: can benign masses be differentiated from malignant ones. Radiology 185:581–586
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
Michaelis LC, Ratain MJ (2006) Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 6:409–414
Blanke C, Demetri G, von Mehren M et al (2008) Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT. J Clin Oncol 26(4):620–625
Dhani N, Tu D, Sargent DJ, Seymour L, et al (2009) Alternate endpoints for screening phase II studies. Clin Cancer Res 15:1873–1882
Van den Abbeele AD, Badawi RD (2002) Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GIST). Eur J Cancer 38:S60–S65
Choi H, Charnsangavej C, Faria SC et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759
Prior J, Montemurro M, Orcurto MV et al (2008) Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor. J Clin Oncol 27:439–445
Stroobants S, Goeminne J, Seegers M et al (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012–2020
Gayed I, Vu T, Iyer R et al (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17–21
Desai J, Shankar S, Heinrich MC et al (2007) Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 13:5398–5405
Lassau N, Lamuraglia M, Chami L et al (2006) Gastro-intestinal stromal tumours treated with imatinib: monitoring response with contrast enhanced ultrasound. Am J Roentgenol 187:1267–1273
Hayashida Y, Yakushiji T, Awai K et al (2006) Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results. Eur Radiol 16:2637–2643
Eilber F, Rosen G, Eckardt J et al (2001) Treatment-Induced Pathologic Necrosis: A Predictor of Local Recurrence and Survival in Patients Receiving Neoadjuvant Therapy for High-Grade Extremity Soft Tissue Sarcomas. J Clin Oncol 19:3203–3209
Collin C, Godbold J, Hajdu S et al (1987) Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 5:601–612
Gaynor JJ, Tan CC, Casper ES et al (1992) Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 10:1317–1329
Evilevitch V, Weber WA, Tap WD et al (2008) Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14:715–720
Benz MR, Czernin J, Allen-Auerbach MS et al (2009) FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15:2856–2863
Dimitrakopoulou-Strauss A, Strauss LG, Egerer G et al (2010) Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med 51:551–558
Tateishi U, Kawai A, Chuman H, et al (2011) PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. Clin Nucl Med 36:526–532
Herrmann K, Benz M, Czernin J et al (2012) 18-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy. Clin Cancer Res 18:2024–2031
Grosso F, Jones R, Demetri G et al (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8:595–602
Casali PG, Messina A, Stacchiotti S et al (2004) Imatinib mesylate in chordoma. Cancer 101:2086–2097
Vanel D, Shapeero LG, De Baere T et al (1994) MR imaging in the follow up of malignant and aggressive soft tissue tumors: results of 511 examinations. Radiology 190:263–268
Panicek D, Schwartz L (1999) MR imaging of bone marrow in patients with musculoskeletal tumors. Sarcoma 3:37–41
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Boukovinas, I.P. (2014). Clinical Implications of Soft Tissue Sarcomas . In: Gouliamos, A., Andreou, J., Kosmidis, P. (eds) Imaging in Clinical Oncology. Springer, Milano. https://doi.org/10.1007/978-88-470-5385-4_12
Download citation
DOI: https://doi.org/10.1007/978-88-470-5385-4_12
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5384-7
Online ISBN: 978-88-470-5385-4
eBook Packages: MedicineMedicine (R0)